CytomX Therapeutics Company Profile (NASDAQ:CTMX)

About CytomX Therapeutics (NASDAQ:CTMX)

CytomX Therapeutics logoCytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CTMX
  • CUSIP: N/A
  • Web:
  • Market Cap: $740.66 million
  • Outstanding Shares: 36,867,000
Average Prices:
  • 50 Day Moving Avg: $18.88
  • 200 Day Moving Avg: $15.92
  • 52 Week Range: $9.85 - $24.67
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -14.30
  • P/E Growth: -7.74
Sales & Book Value:
  • Annual Revenue: $30.13 million
  • Price / Sales: 24.67
  • Book Value: $1.42 per share
  • Price / Book: 14.20
  • EBITDA: ($61,440,000.00)
  • Net Margins: -206.33%
  • Return on Equity: -84.61%
  • Return on Assets: -26.98%
  • Current Ratio: 5.62%
  • Quick Ratio: 5.62%
  • Average Volume: 328,049 shs.
  • Beta: 0.46
  • Short Ratio: 5.05

Frequently Asked Questions for CytomX Therapeutics (NASDAQ:CTMX)

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) issued its quarterly earnings results on Monday, August, 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.30. The business earned $8.75 million during the quarter, compared to analyst estimates of $4.95 million. CytomX Therapeutics had a negative net margin of 206.33% and a negative return on equity of 84.61%. View CytomX Therapeutics' Earnings History.

When will CytomX Therapeutics make its next earnings announcement?

CytomX Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for CytomX Therapeutics.

Where is CytomX Therapeutics' stock going? Where will CytomX Therapeutics' stock price be in 2017?

9 brokerages have issued 1-year target prices for CytomX Therapeutics' stock. Their predictions range from $24.00 to $44.00. On average, they expect CytomX Therapeutics' stock price to reach $32.67 in the next twelve months. View Analyst Ratings for CytomX Therapeutics.

What are analysts saying about CytomX Therapeutics stock?

Here are some recent quotes from research analysts about CytomX Therapeutics stock:

  • 1. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (10/16/2017)
  • 2. Cann analysts commented, "Loss per share was $0.69, compared to our estimate of $0.56. This was the result of higher than expected R&D expense of $28.1 million compared to our estimate of $15.2 million, which resulted from a $10 million payment to UCSB for a sublicense payment. This was partially offset by higher than estimated revenue of $8.8 million compared to our estimated $1.0 million." (8/8/2017)
  • 3. Cowen and Company analysts commented, "CTMX announced that the first patient in CX-2009’s (CD166 PDC) Phase I trial has." (6/28/2017)
  • 4. HC Wainwright analysts commented, "Before the market opened on May 5, TG reported 1Q17 results. The company recently reported preliminary data from its ongoing Phase II study of TG-1101 in patients with relapsing forms of multiple sclerosis. Preliminary results indicated that TG-1101 was well tolerated with no Grade III/IV adverse events (AEs) observed and the most commonly reported AE being infusion-related reactions, with median time on study of five months. All patients achieved the primary endpoint of greater than 95% B-cell depletion by four weeks. The median B-cell depletion at week four was reported to be 99% after two infusions with a cumulative dose of 600 mg, which compares favorably to other anti-CD20 monoclonal antibodies (mAbs). Management indicated that additional data from the ongoing Phase II study will be reported later this year and that the company is on track to initiate a Phase III trial in MS in 2H17." (5/8/2017)
  • 5. Instinet analysts commented, "We are initiating on CytomX Therapeutics (CTMX) with a Buy rating and $21 12-month target price. We recommend owning CTMX shares ahead of 2H17 and 2018 data readouts for CX-072 and CX-2009, which we anticipate will validate the platforms MOA and frame breadth of utility. We remain focused on CX-072 in combo with Zelboraf, on the belief that a strong signal here will provide clear proof-of-concept for the approach, thus limiting downside risk. We look to CX-2009 as an opportunity for potentially significant upside given the high unmet need of solid tumors that express CD166. The potential for value to be ascribed to CTMX pipeline candidates presents upside potential to our estimates." (3/1/2017)

Who are some of CytomX Therapeutics' key competitors?

Who are CytomX Therapeutics' key executives?

CytomX Therapeutics' management team includes the folowing people:

  • Hoyoung Huh Ph.D., Chairman of the Board
  • Sean A McCarthy Ph.D., President, Chief Executive Officer, Director
  • Debanjan Ray, Chief Financial Officer, Principal Financial and Accounting Officer
  • Cynthia Jane Ladd, Senior Vice President, General Counsel
  • W. Michael Kavanaugh M.D., Chief Scientific Officer and Head - Research and Non-Clinical Development
  • Rachel W. Humphrey M.D., Chief Medical Officer
  • Marion McCourt, Director
  • John A. Scarlett M.D., Director
  • Neil Exter, Independent Director
  • Frederick Gluck, Independent Director

How do I buy CytomX Therapeutics stock?

Shares of CytomX Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytomX Therapeutics' stock price today?

One share of CytomX Therapeutics stock can currently be purchased for approximately $20.16.

MarketBeat Community Rating for CytomX Therapeutics (NASDAQ CTMX)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  217
MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for CytomX Therapeutics (NASDAQ:CTMX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.56)
Consensus Price Target: $32.67 (62.04% upside)
Consensus Price Target History for CytomX Therapeutics (NASDAQ:CTMX)
Price Target History for CytomX Therapeutics (NASDAQ:CTMX)
Analysts' Ratings History for CytomX Therapeutics (NASDAQ:CTMX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/5/2017Cowen and CompanyReiterated RatingOutperformN/AView Rating Details
10/4/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldHighView Rating Details
10/4/2017Bank of America CorporationBoost Price TargetBuy$30.00 -> $34.00HighView Rating Details
10/4/2017NomuraBoost Price TargetBuy$44.00HighView Rating Details
10/4/2017WedbushSet Price TargetBuy$26.00 -> $37.00HighView Rating Details
8/25/2017Jefferies Group LLCSet Price TargetBuy$25.00LowView Rating Details
8/8/2017CannReiterated RatingHoldHighView Rating Details
5/8/2017HC WainwrightReiterated RatingBuyLowView Rating Details
3/20/2017InstinetBoost Price TargetSell$21.00 -> $32.00MediumView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for CytomX Therapeutics (NASDAQ:CTMX)
Earnings by Quarter for CytomX Therapeutics (NASDAQ:CTMX)
Earnings History by Quarter for CytomX Therapeutics (NASDAQ CTMX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.11)N/AView Earnings Details
8/7/2017Q2 2017($0.39)($0.69)$4.95 million$8.75 millionViewListenView Earnings Details
5/5/2017Q1 2017($0.55)($0.23)$2.10 million$11.65 millionViewN/AView Earnings Details
3/2/2017Q4 2016($0.45)($0.39)$6.27 millionViewN/AView Earnings Details
11/3/2016Q3($0.35)($0.40)$3.20 million$3.45 millionViewN/AView Earnings Details
8/3/2016Q2($0.41)($0.39)$2.10 million$3.09 millionViewN/AView Earnings Details
5/6/2016Q1 2016($0.26)($0.44)$6.00 million$2.22 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for CytomX Therapeutics (NASDAQ:CTMX)
2017 EPS Consensus Estimate: ($1.91)
2018 EPS Consensus Estimate: ($1.02)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.48)($0.48)($0.48)
Q2 20172($1.04)($0.53)($0.79)
Q3 20173($0.36)($0.01)($0.21)
Q4 20173($0.67)($0.24)($0.44)
Q1 20181($0.21)($0.21)($0.21)
Q2 20181($0.24)($0.24)($0.24)
Q3 20181($0.27)($0.27)($0.27)
Q4 20181($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)


Dividend History for CytomX Therapeutics (NASDAQ:CTMX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for CytomX Therapeutics (NASDAQ:CTMX)
Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 59.97%
Insider Trades by Quarter for CytomX Therapeutics (NASDAQ:CTMX)
Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)
Insider Trades by Quarter for CytomX Therapeutics (NASDAQ:CTMX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/4/2017Frederick W GluckDirectorSell10,000$24.27$242,700.00View SEC Filing  
10/4/2017Robert I TepperMajor ShareholderSell24,777$24.34$603,072.18View SEC Filing  
10/4/2017Sean A MccarthyCEOSell19,120$24.13$461,365.60View SEC Filing  
10/4/2017William Michael KavanaughInsiderSell48,368$24.34$1,177,277.12View SEC Filing  
10/2/2017Debanjan RayCFOSell2,500$18.10$45,250.00View SEC Filing  
10/2/2017Sean A MccarthyInsiderSell9,562$18.57$177,566.34View SEC Filing  
9/26/2017Frederick W GluckDirectorSell5,000$17.30$86,500.00View SEC Filing  
9/19/2017Robert I TepperMajor ShareholderSell20,000$18.00$360,000.00View SEC Filing  
9/1/2017Debanjan RayCFOSell2,500$17.17$42,925.00View SEC Filing  
9/1/2017Sean A MccarthyInsiderSell9,930$17.32$171,987.60View SEC Filing  
8/31/2017Sean A MccarthyInsiderSell18,756$17.50$328,230.00View SEC Filing  
8/9/2017Debanjan RayCFOSell2,500$15.00$37,500.00View SEC Filing  
8/9/2017Sean A MccarthyInsiderSell4,781$15.00$71,715.00View SEC Filing  
7/3/2017Debanjan RayCFOSell2,500$15.47$38,675.00View SEC Filing  
7/3/2017Sean A MccarthyInsiderSell4,781$15.52$74,201.12View SEC Filing  
6/29/2017Robert I TepperMajor ShareholderSell15,000$16.00$240,000.00View SEC Filing  
6/26/2017Frederick W GluckDirectorSell5,000$14.61$73,050.00View SEC Filing  
6/26/2017Sean A MccarthyInsiderSell4,481$15.00$67,215.00View SEC Filing  
6/5/2017Sean A MccarthyInsiderSell300$15.00$4,500.00View SEC Filing  
5/1/2017Sean A MccarthyInsiderSell4,781$15.70$75,061.70View SEC Filing  
4/12/2017Kevin P StarrMajor ShareholderSell28,357$16.36$463,920.52View SEC Filing  
4/4/2017Sean A MccarthyInsiderSell9,562$17.22$164,657.64View SEC Filing  
3/27/2017Rock Ventures Lp ThirdMajor ShareholderSell1,650,000$17.39$28,693,500.00View SEC Filing  
3/20/2017Robert C Goeltz IICFOSell21,517$19.81$426,251.77View SEC Filing  
3/20/2017Sean A MccarthyInsiderSell14,343$19.60$281,122.80View SEC Filing  
3/3/2017Sean A MccarthyInsiderSell14,343$15.00$215,145.00View SEC Filing  
11/28/2016Ix L.P. CanaanDirectorSell38,459$11.56$444,586.04View SEC Filing  
11/22/2016Ix L.P. CanaanDirectorSell42,550$11.71$498,260.50View SEC Filing  
11/21/2016Ix L.P. CanaanDirectorSell45,324$11.61$526,211.64View SEC Filing  
11/16/2016Ix L.P. CanaanDirectorSell51,581$11.50$593,181.50View SEC Filing  
11/15/2016Timothy M ShannonDirectorSell33,064$11.48$379,574.72View SEC Filing  
11/14/2016Ix L.P. CanaanDirectorSell86,270$11.16$962,773.20View SEC Filing  
11/9/2016Ix L.P. CanaanDirectorSell13,730$11.03$151,441.90View SEC Filing  
6/10/2016Timothy M ShannonDirectorSell48,427$10.07$487,659.89View SEC Filing  
6/7/2016Ix L.P. CanaanDirectorSell111,498$10.01$1,116,094.98View SEC Filing  
6/3/2016Ix L.P. CanaanDirectorSell59,621$10.80$643,906.80View SEC Filing  
6/1/2016Ix L.P. CanaanDirectorSell22,463$10.75$241,477.25View SEC Filing  
5/27/2016Ix L.P. CanaanDirectorSell25,082$10.60$265,869.20View SEC Filing  
5/26/2016Timothy M ShannonDirectorSell51,343$10.34$530,886.62View SEC Filing  
5/24/2016Ix L.P. CanaanDirectorSell13,253$10.09$133,722.77View SEC Filing  
5/20/2016Ix L.P. CanaanDirectorSell8,687$10.10$87,738.70View SEC Filing  
10/14/2015Cynthia J LaddVPBuy3,000$12.00$36,000.00View SEC Filing  
10/14/2015Frederick W GluckDirectorBuy15,000$12.00$180,000.00View SEC Filing  
10/14/2015James E FlynnInsiderBuy625,000$12.00$7,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for CytomX Therapeutics (NASDAQ:CTMX)
Latest Headlines for CytomX Therapeutics (NASDAQ:CTMX)
DateHeadline logoCytomX Therapeutics, Inc. (CTMX) Expected to Post Earnings of -$0.11 Per Share - October 20 at 8:28 PM logoCytomX Therapeutics, Inc. (CTMX) Receives Consensus Rating of "Hold" from Analysts - October 19 at 9:38 PM logoCytomX Therapeutics, Inc. (CTMX) Stock Rating Upgraded by Zacks Investment Research - October 16 at 9:24 PM logoContrasting Akari Therapeutics PLC (AKTX) & CytomX Therapeutics (CTMX) - October 16 at 2:11 AM logoShort Interest Expands By 26.7% For CTMX - October 11 at 4:40 PM logoYour Daily Pharma Scoop: Synergy's Cash Position, Flexion's Zilretta Approval, Keryx Major Catalyst - October 10 at 3:21 PM logoAnalysts’ Recommendations for Amgen in October 2017 - October 9 at 3:14 PM logoCancer Space Last Week Update: Pipeline Expansion in Focus - October 9 at 3:13 PM logoWedbush Analysts Give CytomX Therapeutics, Inc. (CTMX) a $37.00 Price Target - October 8 at 11:14 PM logoCytomX Therapeutics, Inc. (CTMX) Price Target Raised to $44.00 at Nomura - October 8 at 6:40 PM logoSean A. Mccarthy Sells 19,120 Shares of CytomX Therapeutics, Inc. (CTMX) Stock - October 6 at 7:26 PM logoCytomX Therapeutics, Inc. (CTMX) Director Sells $242,700.00 in Stock - October 6 at 1:20 PM logoCytomX Therapeutics, Inc. (CTMX) Insider William Michael Kavanaugh Sells 48,368 Shares - October 6 at 1:20 PM logoQ3 2017 EPS Estimates for CytomX Therapeutics, Inc. Cut by Analyst (CTMX) - October 6 at 7:42 AM logoCytomX Therapeutics, Inc. (CTMX) Receives Outperform Rating from Cowen and Company - October 5 at 1:32 PM logoAmgen, CytomX Join in Immuno-Oncology Collaboration - October 5 at 10:48 AM logoCytomX Therapeutics Inc. (CTMX) Jumped To A New High On Amgen Collaboration - October 5 at 10:48 AM logoCytomX Therapeutics, Inc. Forecasted to Earn Q1 2018 Earnings of ($0.21) Per Share (CTMX) - October 5 at 10:40 AM logoCytomX Therapeutics, Inc. (CTMX) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc. - October 4 at 11:44 PM logoCytomX Therapeutics, Inc. (CTMX) Insider Sells $177,566.34 in Stock - October 4 at 10:24 PM logoCytomX Therapeutics, Inc. (CTMX) Expected to Post Quarterly Sales of $17.27 Million - October 4 at 9:32 PM logoInsider Selling: CytomX Therapeutics, Inc. (CTMX) Major Shareholder Sells 24,777 Shares of Stock - October 4 at 7:40 PM logoBank of America Corporation Boosts CytomX Therapeutics, Inc. (CTMX) Price Target to $34.00 - October 4 at 2:02 PM logoInsider Selling: CytomX Therapeutics, Inc. (CTMX) CFO Sells 2,500 Shares of Stock - October 4 at 1:24 PM logoPre-Open Stock Movers 10/04: (CTMX) (CATB) (MYL) Higher; (CLSN) (MNTA) (TEVA) (ODP) Lower (more...) - October 4 at 11:31 AM logoCytomX Therapeutics Inc. (CTMX) Has Jumped To A New High On Amgen News - October 4 at 11:31 AM logoAmgen Enters Into an Immuno-Oncology Partnership With CytomX - October 4 at 11:31 AM logoCytomX Therapeutics Inc. (CTMX) Is Climbing On Amgen Collaboration News - October 3 at 5:29 PM logoETFs with exposure to CytomX Therapeutics, Inc. : October 3, 2017 - October 3 at 5:29 PM logoAmgen And CytomX Therapeutics Announce Strategic Collaboration In Immuno-Oncology - October 3 at 5:29 PM logoCytomX stock rockets 35% after deal with Amgen - October 3 at 5:29 PM logoCytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017 - October 3 at 6:44 AM logoCytomX Therapeutics, Inc. (CTMX) Director Frederick W. Gluck Sells 5,000 Shares - September 27 at 8:08 PM logoCytomX Therapeutics, Inc. (CTMX) Given Average Rating of "Hold" by Brokerages - September 24 at 6:42 PM logoCytomX Therapeutics, Inc. (CTMX) Major Shareholder Robert I. Tepper Sells 20,000 Shares - September 21 at 4:28 PM logoUNITY Biotechnology Appoints Additional Biotech Industry Veterans to Executive Team - September 21 at 9:56 AM logoCytomX to Present at the Cantor Fitzgerald Healthcare Conference - September 13 at 6:54 PM logoCytomX Announces Upcoming Trials in Progress Poster Presentations at European Society for Medical Oncology Annual Meeting - September 8 at 6:00 PM logoCytomX Therapeutics, Inc. (CTMX) Coverage Initiated by Analysts at Wedbush - September 7 at 5:16 PM logoCytomX Therapeutics, Inc. (CTMX) CFO Debanjan Ray Sells 2,500 Shares - September 5 at 8:32 PM logoCytomX Therapeutics, Inc. (CTMX) Insider Sells $171,987.60 in Stock - September 5 at 8:06 PM logoInsider Selling: CytomX Therapeutics, Inc. (CTMX) Insider Sells 18,756 Shares of Stock - September 1 at 8:04 PM logoCytomX Therapeutics, Inc. (CTMX) Given Average Rating of "Hold" by Analysts - August 30 at 6:42 PM logoCytomX Therapeutics, Inc. (CTMX) Expected to Announce Quarterly Sales of $19.15 Million - August 27 at 1:38 AM logoJefferies Group LLC Analysts Give CytomX Therapeutics, Inc. (CTMX) a $25.00 Price Target - August 26 at 8:16 AM logoCytomX Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CTMX-US : August 23, 2017 - August 23 at 7:39 PM logoCytomX Therapeutics, Inc. – Value Analysis (NASDAQ:CTMX) : August 21, 2017 - August 22 at 11:14 PM logoEdited Transcript of CTMX earnings conference call or presentation 7-Aug-17 9:00pm GMT - August 13 at 4:45 PM logoInsider Selling: CytomX Therapeutics, Inc. (CTMX) Insider Sells 4,781 Shares of Stock - August 11 at 1:18 PM logoCytomX to Present at the 2017 Wedbush PacGrow Healthcare Conference - August 10 at 4:32 PM



CytomX Therapeutics (CTMX) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.